

*Embargoed until 1 June 2026 at 00.01. Print media may publish in editions dated 1 June*

## press release

### **Wegovy®▼ (semaglutide injection) 7.2 mg single-dose pen now available in the UK**

- Wegovy (semaglutide) 7.2mg single dose pre-filled injection available in the UK from today, 1 June 2026
- The new pen device provides an additional maintenance administration option for adult patients with obesity, following MHRA approval in April 2026
- The single-dose pen delivers a pre-set 7.2 mg once weekly maintenance dose of semaglutide in a single injection. Previously, the 7.2 mg dose was administered by taking three 2.4 mg injections together once weekly.<sup>1</sup>

**Gatwick, UK, 1 June 2026.** Novo Nordisk today announces that the Wegovy®▼ (semaglutide injection) 7.2 mg single-dose pen is now available in the UK for appropriate adult patients, in line with the licensed indication and local prescribing arrangements.

The single-dose pen delivers a pre-set 7.2 mg once weekly maintenance dose of semaglutide in a single injection. The single-dose pen contains an automatic dosing mechanism with a built-in needle, which is enclosed within a needle cover and locks after use.<sup>2</sup> Previously, the 7.2 mg dose was administered by taking three 2.4 mg injections together once weekly.<sup>3</sup>

The availability of the Wegovy® 7.2 mg single-dose pen provides an additional maintenance administration option for healthcare providers to support eligible patients from today.

In the STEP UP randomised, controlled, phase 3b trial - which evaluated the efficacy and safety of once weekly semaglutide 7.2 mg versus semaglutide 2.4 mg and placebo in adults with obesity - adults treated with semaglutide 7.2 mg achieved mean weight loss of 23 kg (23.27 kg) or 20.7% of baseline body weight at 72 weeks versus 2.7kg (2.4%) with placebo, when used in addition to diet and exercise.<sup>4</sup> Approximately one-third of participants treated with semaglutide 7.2 mg achieved an average weight loss of 28kg (28.10 kg) or ≥25%.<sup>4</sup>

Additional exploratory analyses from the STEP UP trial presented at the European Congress on Obesity (ECO) in May 2026 provided further insights into weight loss outcomes with

semaglutide 7.2 mg.<sup>5</sup> In a post hoc analysis, participants classified as 'early responders', defined as achieving 15% or more weight loss after 24 weeks of treatment, achieved mean weight loss of 27.7% at week 72 with semaglutide 7.2 mg.<sup>5</sup> Early responders represented 26.9% of participants receiving semaglutide 7.2 mg in the analysis.<sup>5</sup>

Obesity is a complex, chronic disease<sup>6</sup> affecting around 15 million people in the UK<sup>7</sup>. The condition requires long-term management and tailored treatment options.<sup>8</sup>

Sebnem Avsar Tuna, General Manager, Novo Nordisk UK said: "The availability of the Wegovy<sup>®</sup> 7.2 mg single-dose device means healthcare professionals now have an additional higher maintenance dose in one single pen, to prescribe for eligible adults who might need to take the next step in their treatment journey."

---

## Notes to Editors

### About availability in the UK

- Wegovy<sup>®</sup> (semaglutide injection) 7.2 mg single-dose pen is now available in the UK following MHRA approval in April 2026.<sup>9</sup>

### About the pen<sup>10</sup>

- The pen delivers a pre-set 7.2 mg dose in a single once weekly injection
- It includes an automatic dosing mechanism with a built-in needle, which locks after use

### About Wegovy<sup>®</sup> (semaglutide injection)

#### Weight Management

Wegovy<sup>®</sup> is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in:

- adults with an initial Body Mass Index (BMI) of  $\geq 30$  kg/m<sup>2</sup> (obesity), or
- adults with an initial Body Mass Index (BMI) of  $\geq 27$  kg/m<sup>2</sup> to  $< 30$  kg/m<sup>2</sup> (overweight) with at least one weight-related comorbidity<sup>2,3</sup>

Treatment should be initiated and supervised by a healthcare professional.

The 7.2 mg dose is approved as a maintenance dose for weight management, if required, for adults with obesity.<sup>2</sup>

For all other indications, please see Wegovy® Summary of Product Characteristics (SmPC).<sup>2,3</sup>

### **Clinical evidence supporting the approval**

The approval of Wegovy® 7.2 mg earlier in 2026<sup>9</sup> was supported by results from the STEP UP randomised, controlled, phase 3b trial, which evaluated the efficacy and safety of once weekly semaglutide 7.2 mg versus semaglutide 2.4 mg and placebo in adults with obesity ( $\geq 30$  kg/m<sup>2</sup>).<sup>4</sup>

In the trial:

- Co-primary endpoints were change in body weight and achievement of  $\geq 5\%$  weight loss, with confirmatory secondary endpoints assessing higher weight-loss thresholds.<sup>4</sup>
- Adults treated with semaglutide 7.2 mg achieved average weight loss of 20.7% of baseline bodyweight at 72 weeks, compared with 2.4% on placebo, in addition to diet and exercise<sup>4</sup>
- Approximately one-third of participants achieved weight loss of 25% or more<sup>4</sup>

### **Safety**

In the STEP UP trial, semaglutide 7.2 mg demonstrated a safety profile consistent with previous trial experience with semaglutide.<sup>2, 4,11</sup>

- The most commonly reported adverse events were gastrointestinal<sup>4</sup>
- The majority were mild to moderate and occurred during dose escalation<sup>4</sup>
- Discontinuation due to gastrointestinal adverse events occurred in:
  - 3.3% participants receiving semaglutide 7.2mg<sup>12</sup>
  - 2% receiving semaglutide 2.4mg<sup>12</sup>
  - 0% placebo<sup>12</sup>

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) for how to report side effects.

---

### **About Novo Nordisk**

*Novo Nordisk is a leading global healthcare company with a heritage of more than 100 years in diabetes care. Building on this foundation, our purpose is to drive change to defeat serious chronic diseases — from diabetes and obesity to rare blood and endocrine disorders — by pioneering scientific breakthroughs, expanding access to medicines, and working to prevent and ultimately cure disease. We are committed to long-term, responsible business practices that deliver financial, social and environmental value. Headquartered in Denmark and operating in around 80 countries, Novo*

Nordisk employs approximately 67,900 people and markets products in roughly 170 countries. For more information, visit [www.novonordisk.co.uk](http://www.novonordisk.co.uk).

## Contacts for further information

### Media:

#### Becky Hess

+44 7825 208077

[rcme@novonordisk.com](mailto:rcme@novonordisk.com)

#### Josefine Older Steffensen

+44 7795 640733

[jdsf@novonordisk.com](mailto:jdsf@novonordisk.com)

## References:

<sup>1</sup> Wegovy 2.4mg Patient Information Leaflet. Available at: [Wegovy 2.4 mg, FlexTouch solution for injection in pre-filled pen - Patient Information Leaflet \(PIL\) - \(emc\) | 13803](#) Last accessed May 2026.

<sup>2</sup> Wegovy 7.2mg Single Dose Pen SmPC. Available at: [Wegovy 7.2 mg Solution for injection in pre-filled pen - Summary of Product Characteristics \(SmPC\) - \(emc\) | 102093](#) Last accessed May 2026.

<sup>3</sup> Wegovy FlexTouch SmPC. Available at: [Wegovy 2.4 mg, FlexTouch solution for injection in pre-filled pen - Summary of Product Characteristics \(SmPC\) - \(emc\) | 13803](#) Last accessed May 2026.

<sup>4</sup> Wharton S, Freitas P, Hjelmessaeth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. *Lancet Diabetes Endocrinol* 2025;13(11):p.949-963;DOI: 10.1016/S2213-8587(25)00226-8

<sup>5</sup> Dicker D, Horn DB, Jacobsen CSF, et al. *Early Responders to Semaglutide 7.2 mg: A Post Hoc Analysis of the STEP UP Trial in Adults with Obesity*. Guided poster presentation at the European Congress on Obesity (ECO) 2026; 12–15 May 2026; Istanbul, Turkey. **Abstract**.

<sup>6</sup> World Health Organization (WHO). Obesity and overweight. 2025. Available at: <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>. Last accessed: May 2026

<sup>7</sup> A Novo Nordisk commissioned report. Frontier Economics. Estimating the full costs of obesity; 26 January 2022. Available from: <https://www.frontier-economics.com/media/hgwd4e4a/the-full-cost-of-obesity-in-the-uk.pdf> Last accessed: May 2026.

<sup>8</sup> NICE. *Overweight and obesity management*. NG246. 2025. Available at: <https://www.nice.org.uk/guidance/ng246/chapter/Discussing-results-and-referral#discussing-results-and-referral-for-adults>. Last accessed: May 2026.

<sup>9</sup> UK Government (2025) 'Single-dose 7.2mg semaglutide (Wegovy) pen approved to treat adult patients with obesity', GOV.UK, 14 April 2026. Available at: <https://www.gov.uk/government/news/single-dose-72mg-semaglutide-wegovy-pen-approved-to-treat-adult-patients-with-obesity> Last accessed: May 2026.

---

<sup>10</sup> Wegovy 7.2mg Patient Information Leaflet. Available at: [Wegovy 7.2 mg Solution for injection in pre-filled pen - Patient Information Leaflet \(PIL\) - \(emc\) | 102093](#) Last accessed May 2026

<sup>11</sup> Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med*. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183.

<sup>12</sup> Supplementary appendix 3 and protocol to Wharton S, et al, 2025. *Lancet Diabetes Endocrinol*. S2213–8587(25): 00226–8.